TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $102.00.

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer increased their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Piper Sandler started coverage on shares of TransMedics Group in a research note on Thursday. They set an “overweight” rating and a $95.00 target price on the stock. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,155,893.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $77.07, for a total value of $1,156,050.00. Following the completion of the transaction, the chief financial officer now owns 13,075 shares in the company, valued at $1,007,690.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 10,000 shares of TransMedics Group stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total transaction of $804,100.00. Following the completion of the transaction, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,155,893.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,949 shares of company stock valued at $7,710,719. Corporate insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently modified their holdings of TMDX. Huntington National Bank bought a new position in shares of TransMedics Group in the second quarter valued at approximately $30,000. Ancora Advisors LLC bought a new position in shares of TransMedics Group in the first quarter valued at approximately $38,000. First Horizon Advisors Inc. boosted its position in shares of TransMedics Group by 45.1% in the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after acquiring an additional 169 shares during the period. Belpointe Asset Management LLC boosted its position in shares of TransMedics Group by 51.6% in the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock valued at $42,000 after acquiring an additional 190 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of TransMedics Group by 595.3% in the second quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock valued at $50,000 after acquiring an additional 512 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.2 %

TMDX opened at $73.94 on Friday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $99.63. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The company has a fifty day moving average of $83.45 and a 200-day moving average of $70.01. The stock has a market cap of $2.42 billion, a PE ratio of -96.03 and a beta of 2.01.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. During the same period in the prior year, the company posted ($0.21) earnings per share. TransMedics Group’s revenue for the quarter was up 158.6% compared to the same quarter last year. On average, sell-side analysts predict that TransMedics Group will post -0.22 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.